BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23011156)

  • 1. MPP3 inactivation by promoter CpG islands hypermethylation in colorectal carcinogenesis.
    Feng X; Chen K; Ye S; Wang H; Wei G; Tan W; Cheng S; Zhang Y; Liu S; Zhou Y
    Cancer Biomark; 2012; 11(2-3):99-106. PubMed ID: 23011156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Promoter hypermethylation and CpG island methylator phenotype in colorectal carcinogenesis].
    Matsubara N
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1659-64. PubMed ID: 20841928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.
    Heller G; Fong KM; Girard L; Seidl S; End-Pfützenreuter A; Lang G; Gazdar AF; Minna JD; Zielinski CC; Zöchbauer-Müller S
    Oncogene; 2006 Feb; 25(6):959-68. PubMed ID: 16205641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer.
    Lee S; Oh T; Chung H; Rha S; Kim C; Moon Y; Hoehn BD; Jeong D; Lee S; Kim N; Park C; Yoo M; An S
    Int J Oncol; 2012 Mar; 40(3):889-98. PubMed ID: 22038115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease.
    Chen K; Wang G; Peng L; Liu S; Fu X; Zhou Y; Yu H; Li A; Li J; Zhang S; Bai Y; Zhang Y
    Int J Cancer; 2011 Jan; 128(2):266-73. PubMed ID: 20340131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
    Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
    Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.
    Aguilera O; Fraga MF; Ballestar E; Paz MF; Herranz M; Espada J; García JM; Muñoz A; Esteller M; González-Sancho JM
    Oncogene; 2006 Jul; 25(29):4116-21. PubMed ID: 16491118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer.
    Lin SY; Yeh KT; Chen WT; Chen HC; Chen ST; Chang JG
    Anticancer Res; 2004; 24(3a):1645-50. PubMed ID: 15274335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
    Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
    Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
    Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
    Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses.
    Chung SK; Lee MG; Ryu BK; Lee JH; Han J; Byun DS; Chae KS; Lee KY; Jang JY; Kim HJ; Chi SG
    Gastroenterology; 2007 Jun; 132(7):2459-77. PubMed ID: 17570219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
    Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
    J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.
    Hellebrekers DM; Lentjes MH; van den Bosch SM; Melotte V; Wouters KA; Daenen KL; Smits KM; Akiyama Y; Yuasa Y; Sanduleanu S; Khalid-de Bakker CA; Jonkers D; Weijenberg MP; Louwagie J; van Criekinge W; Carvalho B; Meijer GA; Baylin SB; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2009 Jun; 15(12):3990-7. PubMed ID: 19509152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of EphA7 by hypermethylation in colorectal cancer.
    Wang J; Kataoka H; Suzuki M; Sato N; Nakamura R; Tao H; Maruyama K; Isogaki J; Kanaoka S; Ihara M; Tanaka M; Kanamori M; Nakamura T; Shinmura K; Sugimura H
    Oncogene; 2005 Aug; 24(36):5637-47. PubMed ID: 16007213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features.
    Lin SY; Yeh KT; Chen WT; Chen HC; Chen ST; Chiou HY; Chang JG
    Oncol Rep; 2004 Feb; 11(2):341-8. PubMed ID: 14719065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.